{"input_url":"https://www.eurekalert.org/news-releases/1143340","gnews_decode":"https://www.eurekalert.org/news-releases/1143340","http_status":200,"final_url":"https://www.eurekalert.org/news-releases/1143340","html_length":112963,"trafilatura_result":"ok","text_length":8385,"text_preview":"Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union","verdict":"OK"}